Statement Of Cash Flows [Abstract]

Innate Pharma - Filing #2811003

Concept 2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for finance income
991,000 EUR
EUR
Cash flows from (used in) operations before changes in working capital
467,000 EUR
6 652 EUR
Increase (decrease) in working capital
32 091 EUR
12 503 EUR
Adjustments for decrease (increase) in trade and other receivables
13 666 EUR
4 204 EUR
Adjustments for increase (decrease) in trade and other payables
3 893 EUR
7 662 EUR
Adjustments for increase (decrease) in deferred income including contract liabilities [abstract]
Adjustments for increase (decrease) in deferred income including contract liabilities
3 998 EUR
23 432 EUR
Adjustments for increase (decrease) in employee benefit liabilities
285,000 EUR
365,000 EUR
Cash flows from (used in) investing activities [abstract]
Purchase of financial instruments, classified as investing activities
EUR
EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.